Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 2 de 2
Filtrer
Plus de filtres










Base de données
Gamme d'année
1.
Nat Med ; 29(6): 1424-1436, 2023 Jun.
Article de Anglais | MEDLINE | ID: mdl-37280275

RÉSUMÉ

Gemcitabine plus cisplatin (GP) chemotherapy is the standard of care for nasopharyngeal carcinoma (NPC). However, the mechanisms underpinning its clinical activity are unclear. Here, using single-cell RNA sequencing and T cell and B cell receptor sequencing of matched, treatment-naive and post-GP chemotherapy NPC samples (n = 15 pairs), we show that GP chemotherapy activated an innate-like B cell (ILB)-dominant antitumor immune response. DNA fragments induced by chemotherapy activated the STING type-I-interferon-dependent pathway to increase major histocompatibility complex class I expression in cancer cells, and simultaneously induced ILB via Toll-like receptor 9 signaling. ILB further expanded follicular helper and helper type 1 T cells via the ICOSL-ICOS axis and subsequently enhanced cytotoxic T cells in tertiary lymphoid organ-like structures after chemotherapy that were deficient for germinal centers. ILB frequency was positively associated with overall and disease-free survival in a phase 3 trial of patients with NPC receiving GP chemotherapy ( NCT01872962 , n = 139). It also served as a predictor for favorable outcomes in patients with NPC treated with GP and immunotherapy combined treatment (n = 380). Collectively, our study provides a high-resolution map of the tumor immune microenvironment after GP chemotherapy and uncovers a role for B cell-centered antitumor immunity. We also identify and validate ILB as a potential biomarker for GP-based treatment in NPC, which could improve patient management.


Sujet(s)
Cisplatine , Tumeurs du rhinopharynx , Humains , Cancer du nasopharynx/traitement médicamenteux , Cancer du nasopharynx/anatomopathologie , Cisplatine/usage thérapeutique , , Tumeurs du rhinopharynx/traitement médicamenteux , Tumeurs du rhinopharynx/étiologie , Tumeurs du rhinopharynx/anatomopathologie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Désoxycytidine/usage thérapeutique , Microenvironnement tumoral
2.
Dent Mater J ; 33(1): 141-6, 2014.
Article de Anglais | MEDLINE | ID: mdl-24492125

RÉSUMÉ

The aim of this study was to investigate the hybrid effects of ZrO2 nanoparticles (nano-ZrO2) and aluminum borate whiskers (ABWs) on flexural strength and surface hardness of denture base resin, polymethyl methacrylate (PMMA). Both nano-ZrO2 and ABWs were modified by silane coupling agent (Z6030) before being mixed with PMMA. Various amounts of silanized nano-ZrO2 and ABWs were mixed with PMMA to prepare ZrO2-ABW/PMMA composites. Flexural strength and surface hardness were evaluated using three- point bending test and Vickers hardness test respectively. Fractured surfaces were also observed by scanning electron microscopy (SEM). The mechanical behaviors of silanized ZrO2-ABW/PMMA composites were significantly improved. Flexural strength reached a maximum value of 108.01 ± 5.54 MPa when 2 wt% of nano-ZrO2 was mixed with ABWs at a ZrO2/ABW ratio of 1:2, amounting to an increase of 52% when compared with pure PMMA. Surface hardness achieved a maximum value of 22.50 ± 0.86 MPa when 3 wt% of nano-ZrO2 was mixed with ABWs at the same ZrO2/ABW ratio, which was an increase of 27% when compared with pure PMMA.


Sujet(s)
Aluminium/composition chimique , Borates/composition chimique , Bases d'appareil de prothèse dentaire , Nanoparticules/composition chimique , Poly(méthacrylate de méthyle)/composition chimique , Zirconium/composition chimique , Dureté , Test de matériaux , Microscopie électronique à balayage , Flexibilité , Silanes/composition chimique , Contrainte mécanique , Propriétés de surface
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...